< Back to previous page
Researcher
Sarah Gerlo
- Keywords:cellular stress, signal transduction, inflammation, molecular biology
- Disciplines:Cell signalling, Molecular and cell biology not elsewhere classified, Inflammation, Innate immunity
Affiliations
- Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → Today - Department of Biochemistry (Department)
Member
From1 Feb 2011 → 30 Sep 2018 - Department of Physiology (Department)
Member
From1 Jan 2009 → 31 Jan 2011 - Department of Biomedical molecular biology (Department)
Member
From1 Oct 2005 → 31 Dec 2008
Projects
1 - 10 of 10
- Generation of a dynamic spatial map of the cellular landscape of HIV-infected gut and its application in unraveling the role of tissue-resident T cells in HIVFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- HIV Nanoheroes: novel CRISPR/Cas9-based CD4+ cell-specific HHV-7 vectors to cure HIVFrom1 Nov 2023 → TodayFunding: FWO Strategic Basic Research Grant
- HIGH-THROUGHPUT, HIGH-SENSITIVITY AND COST-EFFECTIVE MONITORING OF INNATE AND ADAPTIVE IMMUNE RESPONSES AT SINGLE CELL LEVELFrom15 Dec 2022 → TodayFunding: BOF - scientific equipment program
- How do ILCs go wrong: unravelling the mechanisms of ILC depletion and functions in HIV infectionFrom1 Nov 2022 → TodayFunding: FWO fellowships
- Automated system for high-pure extraction of RNA and DNA from samples of limited quantity.From1 Dec 2020 → 30 Nov 2022Funding: BOF - scientific equipment program
- COVID-Trace: from tracking virus-host interactions at the single-cell level to tracing cellular markers for clinical patient stratification.From22 May 2020 → 31 May 2021Funding: FWO Special Call for Covid-19 research projects
- Covid-Track: applying quantitative virology and single-cell genomics to unravel the virus-host interactions leading to severe immunopathologies in COVID-19 patientsFrom15 Apr 2020 → 14 Apr 2021Funding: BOF - projects
- Use of bispecific AcTakines to boost innate and adaptive immune responses after acute HIV-1 infectionFrom15 Nov 2019 → 13 Jan 2024Funding: BOF - doctoral mandates
- Preclinical evaluation of chemogenetics as new treatment for drug-resistant epilepsyFrom1 Jan 2019 → 31 Dec 2022Funding: FWO Strategic Basic Research Grant
- Special Research Fund Professorship in molecular biologyFrom1 Feb 2011 → 31 Jan 2021Funding: BOF - ZAP BOF mandates
Patents
1 - 9 of 9
- CD8 BINDING AGENTS (Inventor)
- Hybrid CAR and Hybrid TCR cells to treat infectious diseases (Inventor)
- CLEC9A BINDING AGENTS AND USE THEREOF (Inventor)
- FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES (Inventor)
- TARGETED MODIFIED IL-1 FAMILY MEMBERS (Inventor)
- TARGETED MODIFIED IL-1 FAMILY MEMBERS (Inventor)
- FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES (Inventor)
- CLEC9A BINDING AGENTS AND USE THEREOF (Inventor)
- CD8 BINDING AGENTS (Inventor)